NeoVista, Inc. Representative Appointed to US Government International Trade Policy Committee

Share Article

Mark Foster Serves as NeoVista Representative on Industry Trade Advisory Committee.

NeoVista, Inc., a privately held company dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD), has announced that Mark E. Foster, Esq. has been appointed by United States Secretary of Commerce Gary Locke and United States Trade Representative (USTR) Ronald Kirk as NeoVista’s representative to the Industry Trade Advisory Committee (ITAC) on Information and Communications Technologies, Services, and Electronic Commerce. ITAC, a unique public-private partnership, engages business leaders in formulating and implementing U.S. trade policy. Foster is counsel on international trade to NeoVista.

As a representative on ITAC, Foster provides policy advice and recommendations to the Secretary of Commerce and the USTR regarding elimination of international trade barriers, negotiating trade agreements between the U.S. and other countries and implementing existing trade agreements affecting the U.S. medical technologies industry. As part of his position, Foster is invited to attend World Trade Organization (WTO) talks to advise trade negotiators on matters of concern to this industry.

At Foster’s appointment, Secretary Locke and USTR Kirk said in a written statement, “Your industry knowledge is critical to the Department of Commerce and Office of the United States Trade Representative in pursuing trade objectives that reflect the concerns and interests of the private sector. We appreciate your willingness to devote your time and effort to the work of our jointly administered Industry Trade Advisory Committees.”

NeoVista President and CEO John Hendrick added, “We are very pleased to be able to work with Secretary of Commerce Locke and USTR Kirk in helping to develop and implement U.S. trade policy that serves the interests of NeoVista, our medical device industry and our nation. Eliminating trade barriers and increasing commerce worldwide are goals that are important to the continued success of NeoVista. We are confident that we will be able to make a positive contribution to the efforts of the United States and our industry in this respect.”

Foster practices law in California’s Silicon Valley and is a partner in Bergeson LLP. Fluent in Japanese, Mr. Foster is a member of the American Law Institute, and is widely recognized as a leading international business and trade lawyer.

About NeoVista, Inc.
NeoVista, Inc. is a privately held medical device company based in Newark, California. NeoVista’s epimacular brachytherapy procedure is currently being studied in a definitive Phase III clinical study to support eventual filing for regulatory approval to market the product in the United States. Following receipt of a CE Mark, NeoVista is now commercializing epimacular brachytherapy in specific European markets, under the product brand name VIDION® Anti-Neovascular (ANV®) Therapy System. For more information about the company, or this novel wet AMD therapy, please visit the company’s Website at


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tony Moses
Visit website